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Objectives. We sought to compare platelet characteristics after
reteplase and alteplase therapy in the setting of the Global Use of
Strategies to Open Occluded Coronary Arteries (GUSTO)-III trial.
Background. Platelet function may be impaired during throm-
bolysis in patients with an acute myocardial infarction. The effects
of reteplase and alteplase on platelet aggregation and major
surface antigen expression during the first 24 h of infarction
therapy are unknown.
Methods. Platelet aggregation and receptor expression by flow
cytometry were determined in 23 patients before thrombolysis and
thereafter at 3, 6, 12 and 24 h.
Results. Aggregation was higher after reteplase at 24 h when
induced by 5 mmol/liter adenosine diphosphate (ADP) (p 5
0.007), 10 mmol/liter ADP (p 5 0.02), collagen (p 5 0.003) and
thrombin (p 5 0.009) than after alteplase. Reteplase therapy
exhibited greater glycoprotein (GP) IIb/IIIa (p 5 0.04), very late
antigen-2 (p 5 0.04) and platelet/endothelial cell adhesion
molecule-1 (p 5 0.002) expression at 24 h. Trends toward
decreased receptor expression early (3 to 6 h), followed by a
progressive increase at 12 h and especially at 24 h occurred after
both agents.
Conclusions. In this prospective clinical ex vivo platelet study,
similar patterns of platelet aggregation and surface receptor
expression occurred during the first 24 h of coronary thrombolysis
with reteplase and alteplase. However, after reteplase, indicators
of platelet activity were higher at 24 h after thrombolysis than
after alteplase. These data suggest that GP IIb/IIIa inhibitors or
other antiplatelet strategies may be particularly advantageous
when used 12 to 24 h after thrombolysis, especially after reteplase
therapy. It is at this time point during the first day of coronary
thrombolysis that GP IIb/IIIa is markedly expressed and platelets
are most active.
(J Am Coll Cardiol 1998;31:1466–73)
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Thrombolytic therapy is the standard treatment for patients
with acute myocardial infarction (AMI). Whereas streptoki-
nase and alteplase are established agents, the clinical efficacy
of reteplase is evolving. Platelets play an important role in the
natural history of AMI. Intravascular platelet activation may
limit reperfusion or cause reocclusion of the recanalized
infarct-related arteries, thus resulting in an overall decreased
effectiveness of thrombolytic therapy (1,2). Glycoprotein (GP)
IIb/IIIa receptor antagonists (3–8) and monoclonal antibodies
(9–11), combined with thrombolytic agents, have been shown
in animal studies and clinical trials to improve reperfusion.
The attempt to determine the platelet-related properties of
thrombolytic agents is not new. There is substantial evidence
from in vitro (12–14) and animal studies (15,16) that impaired
platelet function occurs after thrombolytic therapy. Although
there is agreement that concentrations of substances released
by platelets are elevated after thrombolysis (17–20), there is
no consensus about the dynamics of ex vivo platelet status in
this setting (21–24). Such discrepancies could relate partly
to the particular thrombolytic agent, limitations of the
techniques to assess platelet function, the lack of a standard
method to sample blood and no specified time course to
handle samples. Indeed, the majority of human myocardial
infarction (MI) studies lack a careful, precise description of
the time course of platelet monitoring. The random mea-
surement of platelet function, outside strict time intervals
during MI, has revealed very limited information about
arterial patency, thrombolytic success and possible platelet
involvement in reocclusion, reinfarction and bleeding. Many
clinical studies have examined platelets at unspecified times
or even days after thrombolysis (17,20,22–25), when the
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effects of adjunctive therapy cannot be excluded (26).
Moreover, our knowledge of the status of platelets during
the first 24 h after thrombolysis is very limited, especially
from controlled clinical trials.
The purpose of the present study was to define the imme-
diate and early platelet-related effects of reteplase and alte-
plase in AMI. We assessed platelet aggregation in response to
multiple agonists and determined major surface receptor ex-
pression with flow cytometry at specified times after thrombol-
ysis in patients enrolled in the randomized Global Use of
Strategies to Open Occluded Coronary Arteries (GUSTO-III)
trial.
Methods
The study was approved by the Institutional Review Board
of St. Agnes Hospital and Union Memorial Hospital (Balti-
more, Maryland). Written informed consent was obtained
from all study participants.
Patients. Twenty-three consecutive patients admitted to
the emergency departments of St. Agnes Hospital or Union
Memorial Hospital between July and December 1996 with a
diagnosis of AMI were included. All patients were enrolled in
the GUSTO-III trial of reteplase versus accelerated alteplase
treatment for AMI. The inclusion criteria have been reported
elsewhere (27). In summary, patients of any age who presented
within 6 h of symptom onset with .30 min of continuous
symptoms of AMI and had $1-mm ST segment elevation in
two or more limb leads, $2-mm ST segment elevation in two
or more contiguous precordial leads or bundle branch block on
the 12-lead electrocardiogram were eligible for enrollment.
Patients were excluded for bleeding diathesis; previous stroke,
major operation or significant trauma in the past 6 weeks; or
hypertension .200/110 mm Hg.
Treatments and clinical outcomes. Patients randomized to
receive reteplase received two 10-MU boluses given 30 min
apart. Patients assigned to alteplase received an accelerated
regimen: a 15-mg bolus, then 0.75 mg/kg body weight over
30 min, then 0.50 mg/kg over 1 h. All patients in the current
substudy had received 325 mg of aspirin and at least 5,000 U of
intravenous heparin at baseline sampling. After administration
of thrombolytic therapy, all patients received a continuous
infusion of heparin for the first 24 h after thrombolysis, as
recommended in the GUSTO-III protocol. Eighteen patients
had successful reperfusion and remained free of recurrent
ischemia in the first 24 h of their hospital stay. Three patients
(two with reteplase, one with alteplase) had persistent chest
pain and ST elevation and underwent immediate angiography,
which revealed the absence of reperfusion. Two patients (one
with reteplase, one with alteplase) developed recurrent isch-
emia in the first 24 h and also underwent emergency angiog-
raphy.
Time course and exclusion of blood samples. The sched-
ules for blood drawing, sample preparation and processing
were critical issues of the study design and were monitored by
an independent observer (A.R.S.). The actual timing of blood
collection for the baseline sample was 9.5 6 1.4 min (mean 6
SD) before the start of thrombolytic therapy, 174.6 6 21.8 min
for the 3-h sample, 371.1 6 24.2 min for the 6-h sample,
709.4 6 17.8 min for the 12-h sample and 1,402.9 6 18.8 min
for the 24-h sample. Samples were processed within 1 h after
blood drawing. Four patients (three in the reteplase group, one
in the alteplase group) did not complete the protocol at all
time points. The reasons for early termination were patient
transfer for emergency angioplasty (n 5 3) and inability to
obtain a blood sample (n 5 1). Twenty-three baseline samples,
22 samples collected at 3 h, 20 samples collected at 6 h, 20
samples collected at 12 h and 19 samples collected at 24 h were
included in the analysis.
Platelet aggregation. Blood samples for platelet aggrega-
tion and flow cytometric studies were taken at specified
intervals: in the emergency department immediately before
administration of the thrombolytic therapy and in the coronary
care unit at 3, 6, 12 and 24 h after thrombolytic therapy began.
Citrate and whole blood were immediately mixed in a 1:9
ratio and centrifuged at 1,200 3 g for 2.5 min. The resulting
platelet-rich plasma was kept at room temperature for use
within 1 h. Platelet counts were determined for each plasma
sample with a Coulter counter ZM. Platelet numbers were
adjusted to 3.50 3 108/ml with homologous platelet-poor
plasma. Platelet aggregation was induced by 5 and 10 mmol/
liter adenosine diphosphate (ADP), 1 mg/ml of collagen, 1
mg/ml of thrombin and 1.25 mg/ml of ristocetin. All agonists
were obtained from Chronolog Corporation. Aggregation
studies were performed with a Chronolog Whole Blood Lumi-
Aggregometer (Model 560-Ca). Aggregation was expressed as
the maximal percent change in light transmittance from base-
line, using platelet-poor plasma as a reference at the end of the
recording time. Aggregation curves were recorded for 4 min
and analyzed according to international standards (28).
Flow cytometry. Flow cytometric procedures have been
described elsewhere (29,30) and were performed according to
the manufacturer’s recommendations for sample preparation
and processing. Briefly, venous blood (8 ml) was collected in a
plastic tube containing 2 ml of acid-citrate-dextrose (7.3 g of
citric acid, 22.0 g of sodium citrate 3 2H2O and 24.5 g of
glucose in 1 liter of distilled water) and mixed well. The
mixture was centrifuged at 1,000 rpm for 10 min at room
Abbreviations and Acronyms
ADP 5 adenosine diphosphate
AMI 5 acute myocardial infarction
FITC 5 fluorescein isothiocyanate
GP 5 glycoprotein
GUSTO 5 Global Use of Strategies to Open Occluded Coronary
Arteries
MI 5 myocardial infarction
PAI-1 5 plasminogen activator inhibitor-1
PECAM-1 5 platelet/endothelial cell adhesion molecule-1
TBS 5 Tris-buffered saline
VLA-2 5 very late antigen-2
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temperature. The upper two-thirds of the platelet-rich plasma
was then collected and adjusted to a pH of 6.5 by adding
acid-citrate-dextrose. It was then centrifuged at 1,600 3 g for
10 min. The supernatant was removed, and the platelet pellet
was gently resuspended in 4 ml of washing buffer (10 mmol/
liter Tris/HCl, 0.15 mol/liter NaCl, 20 mmol/liter EDTA, pH
7.4). Platelets were washed in the washing buffer and then in
Tris-buffered saline (TBS) (10 mmol/liter Tris, 0.15 mol/liter
NaCl, pH 7.4). All cells were then divided into 10 plastic
capped tubes. Nine portions of washed platelets were incu-
bated with 5 ml of fluorescein isothiocyanate (FITC)–
conjugated antibodies in darkness at 4°C for 30 min, and one
part remained unstained and served as a negative control.
Surface antigen expression was measured with monoclonal
murine antihuman antibodies to CD9 (p24), CD41 (GP IIb/
IIIa, aIIbb3), CD42b (GP Ib), CD61 (GP IIIa) (DAKO Cor-
poration), CD49b (very late antigen [VLA]-2, or a2b1), CD62p
(P-selectin), CD31 (platelet/endothelial cell adhesion molecule
[PECAM]-1), CD 41b (gp IIb), and CD51/CD61 (avb3, or
vitronectin receptor) (PharMingen). The antibody to the GP
IIb/IIIa receptor has been demonstrated to react with the
platelet population at rest and exhibits a dose-dependent
increase of receptor binding after ADP or thrombin stimula-
tion, or both. After incubation, the cells were washed in TBS
and resuspended in 0.25 ml of 1% paraformaldehyde. Samples
were stored in the refrigerator at 4°C and analyzed with a
Becton Dickinson FACScan flow cytometer with laser output
of 15 mW, excitation at 488 nm and emission detection at
530 6 30 nm. The instrument was calibrated daily with
fluorescence beads (CaliBRITE, Becton Dickinson) and mea-
sured FITC-conjugated fluorescence intensity. All variables
were obtained using four-decade logarithmic amplification.
The data were collected, stored in list mode and then analyzed
using CELLQuest (version 1.2.2) software.
Statistical analysis. A post hoc comparison using the t test
with the Bonferroni correction was performed to identify
specific differences in platelet aggregation and receptor expres-
sion between time points within each treatment group.
Between-treatment comparisons were made at each time point
using t tests (platelet aggregation). A Mann-Whitney U test
was used to analyze nonparametric data (flow cytometry).
Normally distributed data are expressed as mean value 6 SD.
Data distributed otherwise are summarized as medians
(range), and p , 0.05 was considered significant. Differences
between individual flow cytometric histograms were assessed
using the Smirnov-Kolmogorov test incorporated in the
CELLQuest software.
Results
Baseline clinical and demographic characteristics did not
differ substantially between the reteplase and alteplase groups
(Table 1). Three more patients received aspirin daily in the
reteplase group. Groups were also similar in location of
infarction and other baseline clinical and laboratory character-
istics before thrombolysis.
Platelet aggregation. Baseline platelet function did not
differ between groups. In patients treated with alteplase,
platelet aggregability did not differ significantly between the
baseline sample and that at any other time point in response to
all agonists. However, reteplase-treated patients revealed sig-
nificant changes in platelet aggregation induced by all agonists
except ristocetin (Fig. 1). Platelets aggregated significantly
more in response to 5 mmol/liter ADP in the reteplase group at
12 h (p 5 0.04) and 24 h (p 5 0.007) than in the alteplase
group. Compared with baseline values, platelet aggregability
was significantly reduced at 3 h (p 5 0.02) and 6 h (p 5 0.02)
after reteplase therapy. A similar pattern occurred in response
to 10 mmol/liter ADP. Platelets were significantly more active
in the reteplase group after 24 h (p 5 0.02) than in the
alteplase group, and platelet aggregation was significantly
reduced 3 h (p 5 0.03) and 6 h (p 5 0.04) after reteplase
treatment compared with baseline values. In response to the
collagen agonist, platelet aggregation was again significantly
increased in the reteplase group at 24 h (p 5 0.003) compared
with that in the alteplase group. Significant reduction of
platelet aggregability occurred 6 h (p 5 0.009) after reteplase
therapy compared with baseline values. As with collagen
stimulation, the only difference observed between groups after
thrombin inducement was at 24 h, when platelets aggregated
Table 1. Clinical Characteristics of 23 Patients With an Acute
Myocardial Infarction
Reteplase
(n 5 13)
Alteplase
(n 5 10)
Male/female 10/3 8/2
Age (yr) 59.4 6 9.5 62.7 6 8.8
Range 38–79 36–86
Current smoker 6 5
Alcohol use 3 3
Hypertension 8 6
Diabetes 3 2
Prior MI 3 1
Hypercholesterolemia 5 4
Baseline medications
CCBs 3 3
BBs 2 2
ACEIs 1 0
Nitrates 2 1
Diuretic drugs 1 1
Aspirin 5 2
Ant/inf MI 8/5 6/4
Laboratory data
WBCs (3103/ml) 8.2 6 1.6 7.9 6 1.9
RBCs (3106/ml) 3.76 6 0.5 3.59 6 0.5
Platelets (3103/ml) 225.1 6 11.7 238.4 6 10.5
Hemoglobin (g/dl) 15.2 6 0.6 15.4 6 0.5
Hematocrit (%) 40.9 6 3.8 43.7 6 3.9
Creatinine (mg/dl) 1.0 6 0.3 0.9 6 0.4
Time from symptom onset
to thrombolysis (min)
214.5 6 19.8 208.22 6 21.0
Data presented are mean value 6 SD, range or number of patients. ACEIs 5
angiotensin converting enzyme inhibitors; Ant 5 anterior; BBs 5 beta-blockers;
CCBs 5 calcium blockers; inf 5 inferior; MI 5 myocardial infarction; RBCs 5
red blood cells; WBCs 5 white blood cells.
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significantly more in the reteplase group (p 5 0.01). With
ristocetin, platelet aggregation was consistently high, ranging
between 92.6% and 94.1% for reteplase and between 92.7%
and 93.1% for alteplase during the first 24 h after thrombolysis,
with no significant differences between and within groups.
Flow cytometry. Baseline platelet receptor expression did
not differ significantly between the reteplase and alteplase
groups, but substantial changes in receptor expression resulted
after thrombolysis in both groups (Table 2, Fig. 2). Expression
of p24 did not differ significantly between groups at any time
point. Significant decreases in receptor expression compared
with baseline values were seen at 3 h (p 5 0.004) and 6 h (p 5
0.005), followed by an increase (p 5 0.04) at 24 h, after
reteplase therapy. Within the alteplase group, no early recep-
tor inhibition was observed, but at 24 h receptor expression was
higher (p 5 0.01) than that at baseline. Similar receptor
expression patterns were seen with GP Ib in both groups, with
significant inhibition 12 h after either reteplase (p 5 0.02) or
alteplase (p 5 0.007) therapy, but there were no significant
differences between groups.
Although a slight early decrease, followed by an increase, in
GP IIb occurred in both thrombolytic groups, there were no
significant differences between or within the groups. A signif-
icant increase in GP IIIa expression was observed at 12 h (p 5
0.01) and 24 h (p 5 0.0003) after reteplase, but not alteplase,
therapy. Again, these differences were not significant between
groups.
Compared with baseline values, GP IIb/IIIa (aIIbb3) ex-
pression was decreased significantly (p 5 0.03) at 3 h after
reteplase therapy. Its expression was markedly increased at
24 h for reteplase (p 5 0.002) and alteplase (p 5 0.035)
treatment, but significantly more so in the reteplase group (p 5
0.037), which exhibited a nearly threefold increase compared
with baseline values and was twofold higher than that in the
alteplase group. Representative overlapped histograms of
platelets labeled with fluorescent antibodies to GP IIb/IIIa
from patients treated with reteplase or alteplase are presented
in Figure 3.
The only significant difference in platelet VLA-2 (a2b1)
expression between and within groups was an almost threefold
increase in fluorescent intensity among reteplase-treated pa-
tients at 24 h (p 5 0.04) compared with alteplase-treated
patients.
Very similar profiles in P-selectin expression were observed
between groups: Early significant decreases (p 5 0.001 for the
reteplase group; p 5 0.009 for the alteplase group) were
followed by significant increases in its expression (p 5 0.009 for
the reteplase group; p 5 0.02 for the alteplase group).
For PECAM-1, a significant increase (p 5 0.002) in fluo-
rescent intensity occurred in the reteplase group after 24 h
compared with the alteplase group. A significant decrease in its
expression (p 5 0.01) was seen 3 h after reteplase treatment
compared with baseline values.
Dynamic changes in platelet vitronectin receptor (aVb3)
expression were similar between groups; a significant increase
Figure 1. Platelet aggregation in response to administration of 5
mmol/liter ADP (A), 10 mmol/liter ADP (B), collagen (C) and throm-
bin (D) in patients treated with reteplase (circles) versus alteplase
(squares) for AMI. *p , 0.05 between groups.
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occurred at 12 h after thrombolysis with reteplase (p 5 0.04) or
alteplase (p 5 0.04). At 24 h after thrombolysis, vitronectin
receptor expression was even greater in the reteplase group
(p 5 0.008), whereas its expression in the alteplase group
trended toward baseline levels.
Discussion
We determined the ex vivo platelet-related properties of
two thrombolytic agents in patients with an AMI with the
simultaneous use of flow cytometry and conventional aggrega-
tion techniques. We found that reteplase and alteplase, as used
in the GUSTO-III trial, have similar effects on platelet aggre-
gation in response to four agonists. The groups differed only
late after administration (.12 h), in that the reteplase group
showed enhanced aggregability in response to ADP, collagen
and thrombin. In addition, the reteplase group showed mild
early dysfunction (at 3 to 6 h) that was followed by late
enhanced aggregation. We also observed significant changes in
the expression of multiple surface antigens after treatment
with both agents, particularly GP IIb/IIIa, VLA-2 and
PECAM-1 at 24 h.
Platelets and thrombolytic therapy. Failure to reperfuse,
acute reocclusion and severe bleeding complications are major
limitations of systemically given thrombolytic therapy (31,32).
Platelet thrombus formation has been implicated in all these
events. Thus, the effect of thrombolytic therapy on platelet
characteristics are important. Vasoconstriction affected by
platelet release of thromboxane and other mediators, dimin-
ished heparin effects induced by platelet factor 4 and enhanced
thrombin generation on the platelet surface all adversely affect
reperfusion (33). Platelets also interact with both physiologic
and drug-induced fibrinolysis. For example, platelet granules
contain plasminogen activator inhibitor-1 (PAI-1) and alpha2-
antiplasmin (34,35). Release of these proteins can theoretically
result in reduced thrombolysis. Specific binding sites for plas-
minogen (36) and tissue-type plasminogen activator (37) have
been described on the platelet surface. The localization of
these mediators of fibrinolysis to platelets suggests that they
may play an important role in the modulation of clot lysis.
The effect of thrombolytic therapy on platelets has been
extensively debated, with evidence of both platelet activation
and inhibition. Most studies have used in vitro models and
indirect measures of activity, such as the determination of
levels of various mediators and other constituents released
from platelets. The recent use of flow cytometry has enhanced
our knowledge of events that occur on the platelet surface
during activation, allowing the precise measurement of recep-
tors expressed at specified times after thrombolysis. However,
there are few prospective studies of platelet flow cytometry in
patients with an AMI.
Platelet aggregation. In the alteplase group, no significant
changes in aggregation occurred after treatment. These data
are similar to the results of Bertolino et al. (21), who observed
no difference in aggregation in response to 5 mmol/liter ADP
or collagen at 24 h after conventional dosing of alteplase.
However, the significant reduction in aggregation (;40%) at 1
to 3 and at 6 h after drug administration contrasts with our
findings. Ristocetin-induced aggregation was not affected by
alteplase in either study. To our knowledge, there are no
published data on the time course of ex vivo platelet aggrega-
tion in patients with an AMI treated with reteplase.
Receptor expression. In the current study, we saw signifi-
cant changes in the expression of multiple surface antigens
after treatment with both agents. Early after thrombolysis, we
observed only minor (,20%), antigen-specific reductions in
receptor expression, which could reflect excessive plasmin-
induced cleavage or occupancy of the receptor by ligands (38).
The earliest decreases in antigen expression occurred with
platelet antigen 24, GP IIb/IIIa, P-selectin and PECAM-1.
Table 2. Platelet Surface Antigen Expression in Patients With Acute Myocardial Infarction During
First 24 Hours After Thrombolytic Therapy
Group Baseline 3 h 6 h 12 h 24 h
CD9
Reteplase 53.31 6 18.41 41.12 6 13.68* 43.69 6 13.46* 48.62 6 19.73 83.39 6 58.33*
Alteplase 57.58 6 16.28 53.40 6 11.66 58.15 6 15.45 61.14 6 15.32 75.20 6 30.28*
GP IIb
Reteplase 28.76 6 3.08 26.92 6 5.89 27.62 6 5.75 29.77 6 5.64 29.39 6 5.46
Alteplase 27.96 6 1.55 27.92 6 3.60 28.70 6 5.03 29.71 6 4.47 31.25 6 5.47
GP IIIa
Reteplase 318.29 6 48.28 309.54 6 65.01 339.92 6 65.36 349.77 6 64.52* 385.23 6 62.68*
Alteplase 338.25 6 56.52 323.40 6 67.76 329.90 6 82.97 347.36 6 41.04 369.50 6 45.11
P-selectin
Reteplase 31.78 6 4.64 29.90 6 4.68* 30.63 6 3.48 32.54 6 4.26 33.92 6 4.05*
Alteplase 31.23 6 5.59 29.60 6 5.17* 30.00 6 5.21 30.50 6 5.84 32.20 6 5.03*
Vitronectin receptor
Reteplase 59.41 6 22.18 53.62 6 30.49 56.04 6 33.68 73.69 6 44.05* 92.23 6 58.54*
Alteplase 61.12 6 30.64 53.70 6 26.88 60.80 6 32.11 75.30 6 25.55* 68.11 6 27.69
*p , 0.05 versus corresponding baseline measurement. Data presented are mean value 6 SD, expressed as log
fluorescence intensity.
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Later in thrombolysis (.12 h), we observed a marked increase
in specific receptor expression, which was pronounced for
VLA-2, PECAM-1 and GP IIb/IIIa. Bihor et al. (22) studied
three patients treated with alteplase by platelet flow cytometry
using monoclonal antibodies to P-selectin and fibrinogen
bound to GP IIb/IIIa (22). They described GP IIb/IIIa activa-
tion within the first 72 h after treatment, which is in agreement
with our findings.
A decrease in platelet GP Ib expression, observed after 12 h
of reteplase or alteplase therapy, supports previous in vitro
reports that thrombolysis attenuates its expression (39,40) and
contrasts with other in vitro observations in which alteplase
caused no change in its expression (41).
When we compared the effects of reteplase and alteplase,
we found few striking differences in surface antigen expression.
Indeed, from nine receptors studied, at five consecutive time
points, the only significant differences between groups oc-
curred at 24 h. At this time point, greater expression of GP
IIb/IIIa, VLA-2 and PECAM-1 was shown in the reteplase
group. This finding, perhaps the most important of our study,
suggests that adjunctive GP IIb/IIIa inhibitors may be appro-
priately used at a later time point after thrombolysis, when
platelets are most active. The heightened expression of GP
IIb/IIIa, VLA-2 (GP Ia/IIa [a major receptor that binds
collagen] [42]) and PECAM-1 (CD 31) (43) may play a role in
rethrombosis and infarct-related vessel reocclusion.
Our data correlate with the Reteplase Versus Alteplase
Patency Investigation During Myocardial Infarction (RAPID)
trial (31), where reteplase exhibited early patency superior to
that of alteplase. We speculate that the early decrease in
platelet aggregability and receptor expression after reteplase
could be relevant to early reperfusion. However, the GUSTO-
III mortality data did not differ between agents (27). This
finding may be explained in part by increased platelet activa-
tion observed in the reteplase group later at 24 h after
thrombolysis. An intriguing postulate is that late enhanced
platelet activation may be a consequence of early reperfusion
occurring either directly as platelets course through the reper-
fused myocardium or through systemically released mediators.
Another implication of the present study is the failure of
platelet aggregation techniques to detect mild but significant
changes in the platelet status in the alteplase-treated group, as
revealed by flow cytometry. The temporal pattern of platelet
aggregation paralleled the dynamics of receptor expression
more closely in the reteplase group, where the magnitude of
changes was greater.
Limitations of the study. There are several limitations of
the present study, which was designed as a pilot investigation
and therefore has a small sample size. Statistical differences
between groups might be revealed in a larger cohort of
patients. The present report is primarily descriptive and does
not lead to an understanding of the mechanisms of platelet
activity changes after thrombolysis. Moreover, the role of most
of the platelet receptors studied in the pathogenesis of AMI is
still undefined. In addition to the observed differences in
Figure 2. Platelet receptor expression in patients treated with rete-
plase (circles) versus alteplase (squares) for AMI: GP Ib (A), GP
IIb/IIIa (B), VLA-2 (C) and PECAM-1 (D). *p , 0.05 between groups.
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reteplase and alteplase groups, clinical characteristics, such as
use of antecedent aspirin and time of thrombolytic agent
delivery, may have influenced the results. Finally, it is possible
that we missed an early peak of platelet activation, which has
been reported in in vitro and animal experiments.
Conclusions. In this prospective clinical ex vivo platelet
study, similar patterns of platelet aggregation and surface
receptor expression occurred during the first 24 h of coronary
thrombolysis with reteplase and alteplase. However, in patients
treated with reteplase, indicators of platelet activity were
higher at 24 h after thrombolysis than in alteplase-treated
patients. These data suggest that platelet GP IIb/IIIa inhibitors
or other antiplatelet strategies may be particularly advanta-
geous when used 12 to 24 h after thrombolysis, especially after
reteplase therapy. It is at this time point during the first day of
coronary thrombolysis that GP IIb/IIIa is markedly expressed
and platelets are most active.
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